Barclays’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1
| Closed | – | – | 5588 |
|
|
2025
Q2 | $0 | Buy |
+1
| New | – | ﹤0.01% | 5390 |
|
|
2025
Q1 | – | Hold |
0
| – | -$8 | – | 5372 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 5228 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 5239 |
|
|
2024
Q2 | – | Hold |
0
| – | – | – | 4783 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 5010 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 5180 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 4551 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 4423 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 4972 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 5204 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 4933 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 5125 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 5230 |
|
|
2019
Q3 | – | Sell |
-1
| Closed | -$3K | – | 6868 |
|
|
2019
Q2 | $3K | Hold |
1
| – | – | ﹤0.01% | 6758 |
|
|
2019
Q1 | $19K | Sell |
1
-2
| -67% | -$38.7K | ﹤0.01% | 6373 |
|
|
2018
Q4 | $50K | Buy |
3
+2
| +200% | +$68.6K | ﹤0.01% | 5472 |
|
|
2018
Q3 | $31K | Hold |
1
| – | – | ﹤0.01% | 6297 |
|
|
2018
Q2 | $67K | Hold |
1
| – | – | ﹤0.01% | 5480 |
|
|
2018
Q1 | $125K | Hold |
1
| – | – | ﹤0.01% | 5220 |
|
|
2017
Q4 | $106K | Hold |
1
| – | – | ﹤0.01% | 5187 |
|
|
2017
Q3 | $153K | Hold |
1
| – | – | ﹤0.01% | 4629 |
|
|
2017
Q2 | $170K | Buy |
+1
| New | +$497K | ﹤0.01% | 4508 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4244 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 4469 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 5301 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 5146 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6248 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6207 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6915 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 7086 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6970 |
|
Barclays's HEPA Position: Q3 2025 in Review
Barclays sold out of Hepion Pharmaceuticals (HEPA) in Q3 2025, closing a stake of 1 share.
Barclays first reported a position in HEPA in Q2 2017 and held it in 10 quarters. The position peaked at $170K in Q2 2017. 1 fund tracked by Wall St. Rank holds HEPA as of Q3 2025.
- Barclays reported no remaining Hepion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Barclays sold 1 Hepion Pharmaceuticals share in Q3 2025.
- Barclays first reported a position in Hepion Pharmaceuticals in Q2 2017 and held it in 10 quarters.
- Barclays's Hepion Pharmaceuticals position peaked at $170K in Q2 2017.
- 1 fund tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.